Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses
Science Translational Medicine · 2025
DOI: 10.1126/scitranslmed.adv2881 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, 2025. Verfasst von Alexander L Ling und 43 weiteren Autor:innen. Beteiligte Einrichtung: Harvey Cushing Neuro-Oncology Laboratories, Department of Neurosurgery and Center for Tumors of the Nervous System, Mass General Brigham Cancer Insti…. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Recurrent glioblastoma (rGBM) remains incurable. One barrier to the development of effective rGBM therapies is the difficulty in collecting posttreatment tumor tissue. Serial multiomic assays from longitudinal rGBM biopsies may uncover tumor responses to a treatment. Here, we obtained 97 serial rGBM biopsy cores over 4 months from the first two patients participating in a clinical trial of repeated intratumoral dosing of the immunotherapeutic agent CAN-3110. Multiomic analysis of the biopsy cores revealed therapeutic effects, including longitudinal and spatial reshaping of the rGBM’s microenvironment, expansion of new T cell tissue-resident effector memory clonotypes against CAN-3110 epitopes and other undetermined antigens, and expression of human leukocyte antigen (HLA)–presented immunopeptides, including cancer testis antigens. Moreover, serial integrated multimodal analyses provided evidence of therapeutic responses to CAN-3110 despite traditional magnetic resonance imaging indicating progression. Clinically, the two treated patients achieved a pathologic response or stable clinical disease, respectively. These results show the value of longitudinal tissue sampling to understand rGBM’s evolution during administration of an investigational therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Harvey Cushing Neuro-Oncology Laboratories, Department of Neurosurgery and Center for Tumors of the Nervous System, Mass General Brigham Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.
- Surgical Brain Mapping and Molecular Imaging Laboratory, Department of Neurosurgery, Mass General Brigham Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.
- Department of Pathology, Mass General Brigham Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.
- Department of Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.
- James P. Allison Institute, University of Texas MD Anderson Cancer Hospital, Houston, TX 77030, USA.
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
ORCID-Profile: Alexander L Ling, Jennifer Gantchev, Sreyashi Basu, Ryuhjin Ahn, Alicia D'Souza, Anna Ball, Genaro R Villa, Michael S Regan, Gerard Baquer, Georges Ayoub, Charles A Whittaker, Zaki Abou-Mrad, Andres Santos, Dina Elharouni, Jayne Vogelzang, Kenny K H Yu, Hong Chen, Zhong He, Wen Jiang, Calixto Hope Lucas, Haley E Sax, Frederick F Lang, Vinay K Puduvalli, Viviane Tabar, Cameron W Brennan, Matthias Holdhoff, Chetan Bettegowda, Isaac H Solomon, Paul P Tak, Padmanee Sharma, Forest M White, Keith L Ligon, Nathalie Y R Agar, David A Reardon, Giacomo Oliveira, E Antonio Chiocca
Förderung
- NCI NIH HHS
- NINDS NIH HHS
Zitieren
APA
Ling, A. L., Gantchev, J., Prabhu, M. C., Basu, S., Ahn, R., D'Souza, A., Masud, N., Ball, A., Nikas, O., Villa, G. R., Regan, M. S., Baquer, G., Ayoub, G., Whittaker, C. A., Abou-Mrad, Z., Santos, A., Couturier, C. P., Elharouni, D., Vogelzang, J., …, & Chiocca, E. A. (2025). Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.adv2881
Vancouver
Ling AL, Gantchev J, Prabhu MC, Basu S, Ahn R, D'Souza A, et al. Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses. Science Translational Medicine. 2025. doi:10.1126/scitranslmed.adv2881
BibTeX
@article{Ling2025,
author = {Ling, Alexander L and Gantchev, Jennifer and Prabhu, Michael C and Basu, Sreyashi and Ahn, Ryuhjin and D'Souza, Alicia and Masud, Nafisa and Ball, Anna and Nikas, Odysseas and Villa, Genaro R and Regan, Michael S and Baquer, Gerard and Ayoub, Georges and Whittaker, Charles A and Abou-Mrad, Zaki and Santos, Andres and Couturier, Charles P and Elharouni, Dina and Vogelzang, Jayne and Yu, Kenny K H and Chen, Hong and He, Zhong and Jiang, Wen and Lucas, Calixto Hope and Sax, Haley E and Lang, Frederick F and Puduvalli, Vinay K and Tabar, Viviane and W Brennan, Cameron and Boire, Adrienne and Holdhoff, Matthias and Bettegowda, Chetan and Cima, Michael and Solomon, Isaac H and Yuan, Ying and Tak, Paul P and Accelerating GBM Therapies TeamLab, Accelerating GBM Therapies TeamLab and Sharma, Padmanee and White, Forest M and Ligon, Keith L and Agar, Nathalie Y R and Reardon, David A and Oliveira, Giacomo and Chiocca, E Antonio},
title = {Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses},
journal = {Science Translational Medicine},
year = {2025},
doi = {10.1126/scitranslmed.adv2881}
}
EUVIMED